Hetero launches pack of generic Covid-19 drug favipiravir at Rs 2,640

Drug firm Hetero on Friday said it has launched a pack of its generic oral antiviral drug-- Favivir 800/200-- for the treatment of mild-to-moderate symptomatic COVID-19 patients in India.

Favivir 800/200 will be available in a pack containing 16 tablets of favipiravir 800 mg and 2 tablets of favipiravir 200 mg priced at Rs 2,640 per pack, Hetero said in a statement.

The higher strength of Favipiravir 800 mg by the company has been approved by the Drug Controller General of India (DCGI). The product will be marketed and distributed by Hetero Healthcare Ltd, it added.

"The launch of 'Favivir 800/200' is aimed at enhancing patients' adherence to treatment regimen by reducing the number of pills they are required to consume per day," Hetero said.

The product will be made available at all retail medical outlets and hospital pharmacies across the country and sold only on prescription, it added.

The drug is being manufactured at the company's facility in India that is approved by global regulatory authorities.

The company had earlier on July 29, launched its generic version of favipiravir in India under the brand name 'Favivir' after getting the nod from the Indian drug regulator.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel